Logo

RedHill Biopharma Collaborates with NIAID to Investigate RHB-107 (upamostat- WX-671) Against COVID-19

Share this

RedHill Biopharma Collaborates with NIAID to Investigate RHB-107 (upamostat- WX-671) Against COVID-19

Shots:

  • RedHill in collaboration with NIAID will evaluate RHB-107 in non-clinical studies to determine its activity against SARS-CoV-2. The agreement will facilitate the pre-clinical evaluation of RHB-107 as a treatment for COVID-19
  • Additionally- RedHill is evaluating opaganib (Yeliva- ABC294640) against COVID-19. On Apr 17- the company unveils about the compassionate use of Opaganib is underway in Israel- with several patients treated to date and preliminary positive outcomes
  • RHB-107 is a serine protease inhibitor active against trypsins and other related serine proteases- being evaluated in 300+ people across 10 clinical studies- including two completed P-II studies in oncology patients and multiple P-I studies in healthy volunteers and oncology patients

Click here ­to­ read full press release/ article | Ref: RedHill | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions